[go: up one dir, main page]

EA200700876A1 - AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2 - Google Patents

AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2

Info

Publication number
EA200700876A1
EA200700876A1 EA200700876A EA200700876A EA200700876A1 EA 200700876 A1 EA200700876 A1 EA 200700876A1 EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A1 EA200700876 A1 EA 200700876A1
Authority
EA
Eurasian Patent Office
Prior art keywords
angiopoetin
specifically binding
agents specifically
antibodies
fragments
Prior art date
Application number
EA200700876A
Other languages
Russian (ru)
Other versions
EA011866B1 (en
Inventor
Джонатон Даниел Олайнер
Кевин Грэхэм
Original Assignee
Амджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Амджен Инк. filed Critical Амджен Инк.
Publication of EA200700876A1 publication Critical patent/EA200700876A1/en
Publication of EA011866B1 publication Critical patent/EA011866B1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Раскрыты специфические связывающие агенты, такие как полностью человеческие антитела, которые связывают ангиопоэтин-2. Раскрыты также фрагменты тяжёлых цепей, фрагменты лёгких цепей и участки, определяющие комплементарность (CDR), в составе антител, а также способы получения и применения этих антител.Specific binding agents are disclosed, such as fully human antibodies that bind angiopoietin-2. Also disclosed are fragments of heavy chains, fragments of light chains, and regions that determine complementarity (CDR) in the composition of antibodies, as well as methods for producing and using these antibodies.

EA200700876A 2004-10-19 2005-10-19 Angiopoetin-2 specific binding agents EA011866B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (2)

Publication Number Publication Date
EA200700876A1 true EA200700876A1 (en) 2007-10-26
EA011866B1 EA011866B1 (en) 2009-06-30

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700876A EA011866B1 (en) 2004-10-19 2005-10-19 Angiopoetin-2 specific binding agents

Country Status (10)

Country Link
JP (2) JP2008520188A (en)
CN (1) CN101495513B (en)
BR (1) BRPI0518209A (en)
EA (1) EA011866B1 (en)
IL (1) IL182279A0 (en)
MA (1) MA29015B1 (en)
MX (1) MX2007004247A (en)
RU (2) RU2404992C2 (en)
SG (1) SG156668A1 (en)
ZA (1) ZA200704020B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011866B1 (en) * 2004-10-19 2009-06-30 Амджен Инк. Angiopoetin-2 specific binding agents
JO3182B1 (en) * 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
EA022546B1 (en) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Method for inhibiting growth of ehrlich carcinoma in laboratory animal
EP3210625B1 (en) * 2011-09-30 2019-08-28 Dana-Farber Cancer Institute, Inc. Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
NZ627859A (en) * 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (en) * 2014-05-19 2016-09-21 Lilly Co Eli ANTIBODIES ANG2
CN106660964B (en) 2014-08-28 2021-09-03 卫材R&D管理有限公司 High-purity quinoline derivative and process for producing the same
PL3263106T3 (en) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (en) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer
ES2886107T3 (en) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplastic
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
CN106512006A (en) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Application of ANGPT2 secretion inhibitor to preparation of medicine for treating hemangiomas
CN106075448A (en) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 ANGPT2 inhibitor is used for treating the application in angiomatous medicine in preparation
MX380144B (en) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd PHARMACEUTICAL COMPOSITION FOR TUMOR TREATMENT.
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109096368B (en) * 2018-09-30 2021-07-20 华南理工大学 A polypeptide having both anti-oxidative and liver-protecting activities, a gene encoding the polypeptide, and a preparation method and application thereof
CN113728004A (en) * 2019-02-25 2021-11-30 药物抗体公司 anti-Ang 2 antibodies and uses thereof
CN112126671B (en) * 2020-08-18 2021-08-31 中山大学附属第五医院 Application of Streptococcus agalactiae in the treatment of endometriosis
CN116265487B (en) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 Anti-ANG 2-VEGF bispecific antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540165A (en) * 1999-03-26 2002-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Regulation of vascular permeability by TIE2 receptor activator
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
ATE363291T1 (en) * 2000-06-23 2007-06-15 Bayer Schering Pharma Ag COMPOSITIONS THAT INTERFER WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTIONS
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EP1458367B2 (en) * 2001-10-12 2021-01-27 Aquestive Therapeutics, Inc. Uniform films for rapidly dissolving dosage form incorporating taste-masking compositions
EA011866B1 (en) * 2004-10-19 2009-06-30 Амджен Инк. Angiopoetin-2 specific binding agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
US9534007B2 (en) 2012-12-21 2017-01-03 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity

Also Published As

Publication number Publication date
EA011866B1 (en) 2009-06-30
CN101495513A (en) 2009-07-29
ZA200704020B (en) 2008-06-25
IL182279A0 (en) 2007-07-24
RU2007118670A (en) 2008-12-27
RU2010132956A (en) 2012-02-10
RU2404992C2 (en) 2010-11-27
BRPI0518209A (en) 2008-11-04
JP2008520188A (en) 2008-06-19
CN101495513B (en) 2014-08-06
SG156668A1 (en) 2009-11-26
MA29015B1 (en) 2007-11-01
MX2007004247A (en) 2007-06-12
JP2011207882A (en) 2011-10-20

Similar Documents

Publication Publication Date Title
EA200700876A1 (en) AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
EA200400526A1 (en) AGENTS SPECIFICALLY CONNECTING WITH HUMAN ANGIOPOETIN-2
EA201001335A1 (en) ANTIBODIES DIRECTED AGAINST ANGIOPOETHINA-1 AND ANGIOPOETINA-2 AND THEIR APPLICATION
EA201070888A1 (en) ANTIBODIES AND THEIR DERIVATIVES
EA200800812A1 (en) Antibody Anti-CD3 Compositions
LUC00025I2 (en)
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
EP1912674B8 (en) Bispecific single chain fv antibody molecules and methods of use thereof
EA200700175A1 (en) COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY DISEASES
NO20171697A1 (en) IL-17 Antagonistic Antibodies
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
PH12015501848A1 (en) Binding agents
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
IL184617A (en) Anti-dr5 antibody comprising mutations in the heavy and light chain of full- length antibody 16e2 and various aspects associated therewith
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
GEP20074222B (en) Antibodies to cd40
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
EA200801172A1 (en) LIGANDS HAVING A SPECIFICITY OF BINDING WITH RESPECT TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR (EGFR) AND / OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND THEIR APPLICATION
ATE545657T1 (en) TGF-BETA ANTIBODIES
EA201491575A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
WO2008133641A3 (en) Antibodies directed to gpnmb and uses thereof
TW200635946A (en) Binding proteins specific for human matriptase

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU